NasdaqGS:EWTXPharmaceuticals
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich
Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period.
See our latest analysis for Edgewise Therapeutics.
Despite the wider loss, Edgewise Therapeutics shares have shown strong momentum, with a 30 day share price return of 11.09% and an 85.98% year to date share price return. The 1 year total shareholder return of 212.16% and 3 year total shareholder...